Forms of rifaximin and uses thereof
View Patent ↗The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
1. A rifaximin polymorph mesylate Form, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree θ) at
5.34, 6.93, and 7.41; or
5.34, 16.23, and 17.70; or
5.34, 7.41, 8.46, and 10.62; or
6.93, 8.46, 10.62, and 10.95; or
6.93, 7.41, and 8.46; or
5.34, 6.93, 7.41, and 17.94; or
5.34, 6.93, 7.41, 8.46, and 10.62.
2. The rifaximin polymorph mesylate Form of claim 1 , wherein the polymorph is at least 50% pure, or at least 75% pure, or at least 80% pure, or at least 90% pure, or at least 95% pure, or at least 98% pure.
3. A pharmaceutical composition comprising rifaximin polymorph mesylate Form of claim 1 , and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , further comprising one or more pharmaceutically acceptable excipients.
5. The pharmaceutical composition of claim 4 , wherein the excipient comprises one or more of a diluting agent, binding agent, lubricating agent, disintegrating agent, coloring agent, flavoring agent or sweetening agent.
6. The pharmaceutical composition of claim 3 , formulated as coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets or powders in sealed packets.
7. The pharmaceutical composition of claim 3 , formulated for topical use.
8. A method of treating a bowel related disorder comprising administering to a subject in need thereof an effective amount of rifaximin polymorph mesylate Form of claim 1 .
9. The method according to claim 8 , wherein the subject is suffering from at least one bowel related disorder selected from the group consisting of irritable bowel syndrome, travelers' diarrhea, small intestinal bacterial overgrowth, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, enteritis and colitis.
10. A process of producing rifaximin polymorph mesylate Form of claim 1 , comprising letting stand at ambient conditions for about 1 hour, a rifaximin filtrate.
11. A rifaximin polymorph mesylate Form, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ (+/−0.20 degree 0) at
17.70, 19.29, and 22.77; or
16.23, 17.70, and 17.94; or
10.62, 10.95, 16.23, 17.70, 17.94, and 19.29; or
5.34, 6.93, 7.41, 8.46, 10.62, 10.95, and 16.23; or
5.34, 6.93, 7.41, 8.46, 10.62, 10.95, 16.23, 17.70, 17.94, 19.29, 22.77, 24.81, and 27.81; or
16.23, 17.70, 17.94, 19.29, and 22.77; or
5.34, 6.93, 7.41, 8.46, 10.62, 10.95, 16.23, 17.70, 17.94, 19.29, and 22.77.
12. The rifaximin polymorph mesylate Form of claim 11 , wherein the polymorph is at least 50% pure, or at least 75% pure, or at least 80% pure, or at least 90% pure, or at least 95% pure, or at least 98% pure.
13. A pharmaceutical composition comprising rifaximin polymorph mesylate Form of claim 11 , and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , further comprising one or more pharmaceutically acceptable excipients.
15. The pharmaceutical composition of claim 14 , wherein the excipient comprises one or more of a diluting agent, binding agent, lubricating agent, disintegrating agent, coloring agent, flavoring agent or sweetening agent.
16. The pharmaceutical composition of claim 13 , formulated as coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets or powders in sealed packets.
17. The pharmaceutical composition of claim 13 , formulated for topical use.
18. A method of treating a bowel related disorder comprising administering to a subject in need thereof an effective amount of rifaximin polymorph mesylate Form of claim 1 .
19. The method according to claim 18 , wherein the subject is suffering from at least one bowel related disorder selected from the group consisting of irritable bowel syndrome, travelers' diarrhea, small intestinal bacterial overgrowth, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, enteritis and colitis.
20. A process of producing rifaximin polymorph mesylate Form of claim 11 , comprising letting stand at ambient conditions for about 1 hour, a rifaximin filtrate.